Evidence map›Paper›PMID 34837976›Full record

ArticleBMC psychiatry2021

A randomized controlled trial of cognitive control training (CCT) as an add-on treatment for late-life depression: a study protocol.

Bart Meuleman, Janna N Vrijsen, Marie-Anne Vanderhasselt, Ernst H W Koster, Peter Oostelbos, Paul Naarding, Linda Bolier, Indira Tendolkar, Filip Smit, Jan Spijker and 1 more

Open access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in BMC psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Bart MeulemanDepression Expertise Centre, Pro Persona Mental Health Care, Nijmeegsebaan 61, 6525 DX, Nijmegen, the Netherlands. bart.meuleman@ru.nl.ORCID 0000-0002-0515-4987
Janna N VrijsenDepression Expertise Centre, Pro Persona Mental Health Care, Nijmeegsebaan 61, 6525 DX, Nijmegen, the Netherlands.
Marie-Anne VanderhasseltDepartment of Experimental Clinical and Health Psychology, Ghent University, Ghent, Belgium.
Ernst H W KosterDepartment of Experimental Clinical and Health Psychology, Ghent University, Ghent, Belgium.
Peter OostelbosDutch Depression Association, Amersfoort, The Netherlands.
Paul NaardingGGNet Network for Mental Health Care, Zutphen, the Netherlands.
Linda BolierTrimbos Institute (Netherlands Institute of Mental Health and Addiction), Utrecht, the Netherlands.
Indira TendolkarDonders Institute for Brain, Cognition and Behaviour, Department of Psychiatry, Radboud University Medical Center, Nijmegen, the Netherlands.
Filip SmitTrimbos Institute (Netherlands Institute of Mental Health and Addiction), Utrecht, the Netherlands.
Jan SpijkerDepression Expertise Centre, Pro Persona Mental Health Care, Nijmeegsebaan 61, 6525 DX, Nijmegen, the Netherlands.
Eni S BeckerBehavioural Science Institute, Radboud University Nijmegen, Nijmegen, the Netherlands.
Radboud University Nijmegen · NLGhent University Hospital · BETrimbos Institute · NLGGNet · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlready a major health concern, late-life depression (LLD) is expected to form an increasing problem in the aging population. Moreover, despite current treatments, LLD is associated with a poor long-term prognosis and high rate of chronicity. Treatment provision and treatment accordingly warrant improvement, where add-on treatments might contribute to the efficacy of conventional therapies. Although it is known that impaired cognitive control contributes to LDD, it is not targeted sufficiently by current interventions. Research on cognitive control training (CCT) shows promising results on depressive symptoms, cognitive performance, and overall functioning. However, further research is needed to determine the long-term effects of CCT on LLD, its cost-effectiveness, and mechanisms of change.

methodsIn the current multicenter randomized controlled trial (RCT) with a between-subjects design participants aged 60 years and over with a current LLD receiving treatment as usual (TAU) are randomized to add-on CCT or placebo training. Randomization is stratified by depression severity. Participants will receive eight online CCT or placebo sessions spread across four consecutive weeks. They will complete a post-training assessment after 1 month and three follow-up assessments scheduled three, six and 12 months after completing the training. We expect CCT and TAU to be more (cost-)effective in reducing depressive symptoms than placebo training and TAU. Additionally, we will be looking at secondary clinical, cognitive and global functioning outcomes and likely mechanisms of change (e.g., improved cognitive functioning, reduced rumination, and improved inhibition of negative stimuli). DISCUSSION: The proposed RCT aims to contribute to the clinical and scientific knowledge on the long-term effects of CCT as an add-on treatment for LLD. Cost-effectiveness is particularly relevant considering the expected volume of the target demographic. The study will be a pragmatic trial with few inclusion restrictions, providing information on feasibility of web-based trainings in clinical settings. The outcomes are potentially generalizable to guidelines for treatment of LLD.

trial registrationThis trial is registered in the Netherlands Trial Register (code: NL7639 ). Registered 3 april 2019.

Indexed as

Cognitive DysfunctionDepressionAgedCognitionCost-Benefit AnalysisHumansMiddle AgedMulticenter Studies as TopicPragmatic Clinical Trials as TopicRandomized Controlled Trials as TopicTreatment OutcomeCognitive control(cost-)effectivenessLate-life depression

Identifiers

PMID34837976
PMCPMC8626726
OpenAlexW3216129056

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.